nirogacestat (Ogsiveo) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Priority Review FDA
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc3cn(cn3)C(C)(C)CNCC(C)(C)C
  • InChIKey: VFCRKLWBYMDAED-REWPJTCUSA-N
  • Mol. Mass: 489.66
  • ALogP: 4.79
  • ChEMBL Molecule:
    nirogacestat  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide | nirogacestat | pf03084014 | pf 03084014 | pf-03084014 | pf3084014 | pf 3084014 | pf-3084014

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Fibroma (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Blood Protein Disorders (Phase 1/Phase 2)

Breast Neoplasms (Phase 2)

Corneal Diseases (Phase 1/Phase 2)

Fibromatosis, Aggressive (Phase 3)

Hematology (Phase 1/Phase 2)

HIV Infections (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 3)

Neoplasms by Histologic Type (Phase 1)

Neoplasms, Plasma Cell (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Paraproteinemias (Phase 1/Phase 2)

Sarcoma, Kaposi (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue